Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis
Cleveland Clinic Journal of Medicine. 2003 July;70(7):585-586, 589-590, 592-594, 597-598, 600-601
July 1, 2003|Cleveland Clinic Journal of Medicine
Author and Disclosure Information
ABSTRACTForteo (teriparatide of rDNA origin), a genetically engineered fragment of parathyroid hormone, is the first of a new class of drugs to treat osteoporosis. The drug's anabolic action increases bone turnover, stimulating osteoblasts to a greater extent than osteoclasts, and reducing both vertebral and nonvertebral fractures. However, a number of issues about its use remain unanswered.
